GlassScriptPhysician profile
Marvin Rios
NPI 1992190680
$5,195.67
in general payments reported to CMS, 2019-2025
31 companies · $464 in 2025
The $464 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $110 · 2021: $1,101 · 2022: $1,838 · 2023: $1,368 · 2024: $315 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116 · Entertainment: $31.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,115.53 |
| Entertainment | $31.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $526.47 | 2022-2023 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $492.25 | 2020-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $467.21 | 2021-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $431.20 | 2021-2023 | Korlym |
| Astrazeneca Pharmaceuticals LP | $413.66 | 2020-2022 | |
| Lilly USA, LLC | $378.50 | 2020-2023 | Jardiance, Lyumjev, Trulicity |
| Beta Bionics, INC. | $308.82 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $282.52 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $280.79 | 2021-2023 | Prolia, Evenity |
| Medtronic, INC. | $265.71 | 2021-2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $224.58 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $196.90 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Antares Pharma, INC. | $138.74 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Insulet Corporation | $102.50 | 2024 | Omnipod |
| Amarin Pharma, INC. | $101.12 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.84 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $81.88 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $45.98 | 2023 | |
| Radius Health, INC. | $40.43 | 2023 | Tymlos |
| Recordati_rare_diseases_inc. | $38.74 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $33.51 | 2021 | |
| Halozyme INC | $32.71 | 2023 | |
| Sequel Med Tech, LLC | $32.25 | 2025 | Twiist |
| Lifescan, INC. | $32.14 | 2021-2022 | |
| Optos, INC. | $31.63 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Ascendis Pharma Endocrinology INC | $24.60 | 2023 | |
| Sanofi-Aventis U.S. LLC | $23.79 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $21.45 | 2023 | Crysvita |
| Medtronic Minimed, INC. | $20.49 | 2020 | |
| Amryt Pharma Holdings LTD | $17.03 | 2023 | Mycapssa |
| Zealand Pharma US, INC. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.